Loading...
•
Jun 30, 2022
Integra LifeSciences Q2 2022 Earnings Report
Integra LifeSciences' second quarter performance was marked by revenue growth and strategic advancements.
Key Takeaways
Integra LifeSciences reported a 2.0% increase in second-quarter revenues to $398 million, with organic growth of 4.8%. GAAP earnings per diluted share were $0.54, up from $0.41 in the prior year, and adjusted earnings per diluted share were $0.82, compared to $0.79 in the prior year. The company has tightened its full-year 2022 organic growth guidance to 4.0% to 5.2%.
Second quarter revenues increased by 2.0% on a reported basis and 4.8% on an organic basis.
GAAP earnings per diluted share increased to $0.54, compared to $0.41 in the prior year.
Adjusted earnings per diluted share increased to $0.82, compared to $0.79 in the prior year.
The company entered into an agreement to sell its non-core traditional wound care business.
Forward Guidance
The Company is tightening its organic growth expectations from a prior range of 3.8% to 5.2% to an updated range of 4.0% to 5.2%. Full year 2022 reported revenue guidance has been revised to a range of $1,557 million to $1,575 million, representing reported growth of 1.0% to 2.1%. Full year 2022 adjusted earnings per diluted share guidance is updated to a range of $3.21 to $3.29
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...